Fair Value Measurements (Narrative) (Detail) (USD $) In Thousands, unless otherwise specified	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2011	Mar. 31, 2013		Mar. 31, 2013		Mar. 31, 2012	Jun. 30, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Foreign currency contracts outstanding, notional amount		$ 64,484		$ 64,484
Unrealized gains (losses) on hedging activities				218		221
Interest rate swap designated as a cash flow hedge, notional amount	20,000
Interest rate swap designated as a cash flow hedge, expiration date	Dec. 31, 2015
Unrealized loss on interest rate swap		318
Contingent consideration at fair value		4,811	[1]	4,811	[1]		1,779	[2]
Business acquisition, additional contingent consideration accrued				2,840
Rising Pharmaceuticals Inc.
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration at fair value		4,811		4,811			1,779
Contingent consideration, accrued interest expense		192
Business acquisition, additional contingent consideration accrued		$ 2,840

[1] Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2012.

[2] Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2012.